Exact Sciences Corp (EXAS)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Exact Sciences Corp (EXAS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014321
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Exact Sciences Corp (Exact) is a molecular diagnostic company that focuses on the early detection and prevention of various cancers. The company’s flagship product, Cologuard test is a non-invasive stool-based deoxyribonucleic acid (DNA) screening product indicated for the early detection of colorectal cancer and pre-cancer. It utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer. The company is also working on the development of additional tests for other types of cancers and identified proprietary methylation markers for several major cancers. It operates a laboratory facility in Madison, Wisconsin to process Cologuard tests. Exact is headquartered in Madison, Wisconsin, the US.

Exact Sciences Corp (EXAS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Exact Sciences Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Exact Sciences Corp, Medical Devices Deals, 2011 to YTD 2017 9
Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Exact Sciences Corp, Pharmaceuticals & Healthcare, Deal Details 11
Equity Offering 11
Exact Sciences Raises USD245 Million in Public Offering of Shares 11
Exact Sciences Prices Public Offering of Shares for USD178.5 Million 13
Exact Sciences Completes Public Offering Of Shares For US$146.6 Million 14
Exact Sciences Completes Public Offering Of Shares For US$78 Million 16
Exact Sciences Completes Public Offering of Common Stock For US$62 Million 17
Exact Sciences Corp – Key Competitors 18
Exact Sciences Corp – Key Employees 19
Exact Sciences Corp – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Financial Announcements 21
Jul 25, 2017: Cologuard revenue increased to $57.6 million during second quarter; Test volume grew 149 percent from second quarter of 2016 to 135,000 completed tests 21
Feb 21, 2017: Exact Sciences reports lower Q4 net loss, provides outlook for 2017 22
Feb 24, 2016: Exact Sciences Reports Fourth Quarter and Full Year 2015 Results 23
Jan 11, 2016: Exact Sciences Announces Preliminary Fourth Quarter and Full Year 2015 Results 24
Corporate Communications 25
Nov 08, 2016: Exact Sciences Appoints Jeff Elliott Chief Financial Officer 25
Jan 25, 2016: Exact Sciences announces appointment of John A. Fallon, M.D., to company’s board of directors 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
Exact Sciences Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Exact Sciences Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Exact Sciences Corp, Deals By Therapy Area, 2011 to YTD 2017 8
Exact Sciences Corp, Medical Devices Deals, 2011 to YTD 2017 9
Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Exact Sciences Raises USD245 Million in Public Offering of Shares 11
Exact Sciences Prices Public Offering of Shares for USD178.5 Million 13
Exact Sciences Completes Public Offering Of Shares For US$146.6 Million 14
Exact Sciences Completes Public Offering Of Shares For US$78 Million 16
Exact Sciences Completes Public Offering of Common Stock For US$62 Million 17
Exact Sciences Corp, Key Competitors 18
Exact Sciences Corp, Key Employees 19
Exact Sciences Corp, Subsidiaries 20

★海外企業調査レポート[Exact Sciences Corp (EXAS)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Rockwool International AS:戦略・SWOT・企業財務分析
    Rockwool International AS - Strategy, SWOT and Corporate Finance Report Summary Rockwool International AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Sensorion SA (ALSEN):企業の財務・戦略的SWOT分析
    Summary Sensorion SA (Sensorion) is a biopharmaceutical company that develops therapies. The company provides treatments for vestibular and cochlear pathologies. It develops drug candidates through its technology platform for the treatment of various therapeutic areas including vestibular neuritis, …
  • Sompo Japan Nipponkoa Holdings, Inc.:戦略・SWOT・企業財務分析
    Sompo Japan Nipponkoa Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Sompo Japan Nipponkoa Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Eisai Inc:企業のM&A・事業提携・投資動向
    Eisai Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Eisai Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Montisera Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Montisera Ltd (Montisera) focuses on discovering, developing and commercialising bioactive compounds and molecules for pharmaceutical and food industries. Its pipeline portfolio includes Montisera D15 1 for alcoholism; Montisera D 4 for treating lower urinary tract symptoms, Montisera D15 2 …
  • British Business Bank Plc:企業の戦略的SWOT分析
    British Business Bank Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Palfinger AG (PAL):企業の財務・戦略的SWOT分析
    Palfinger AG (PAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Sensus Healthcare Inc (SRTS):製品パイプライン分析
    Summary Sensus Healthcare Inc (Sensus), previously Sensus Healthcare LLC, designs, manufactures, and markets proprietary medical devices for the treatment of various types of cancers and skin diseases. The company offers superficial radiation therapy (SRT) technology based non-surgical treatment opt …
  • Venture Life Group Plc (VLG)-製薬・医療分野:企業M&A・提携分析
    Summary Venture Life Group Plc (Venture Life) is a consumer goods company that offers ageing population products. The company's product range and pipeline comprise food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medica …
  • Republic Services Inc (RSG):企業の財務・戦略的SWOT分析
    Republic Services Inc (RSG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Marksmen Energy Inc (MAH):企業の財務・戦略的SWOT分析
    Summary Marksmen Energy Inc (Marksmen Energy), formerly Marksmen Resources Ltd is an oil and gas exploration and development company that explores and develops light oil assets in Ohio. The company acquires, explores, operates, mines, manages, produces and develops oil and gas properties in Western …
  • SGL Carbon SE (SGL):企業の財務・戦略的SWOT分析
    SGL Carbon SE (SGL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Poupart Limited:企業の戦略・SWOT・財務情報
    Poupart Limited - Strategy, SWOT and Corporate Finance Report Summary Poupart Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Pear Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Pear Therapeutics Inc (Pear Therapeutics) develops software-based prescription digital therapeutics for the treatment of severe medical conditions and diseases. Its product pipeline includes reSET-O for treating opioid use disorder (OUD) in conjunction with opioid replacement therapy; Thrive …
  • DBS Bank Ltd:企業のM&A・事業提携・投資動向
    DBS Bank Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's DBS Bank Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Top Image Systems Ltd. (TISA):企業の財務・戦略的SWOT分析
    Top Image Systems Ltd. (TISA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • ValiRx Plc (VAL):企業の財務・戦略的SWOT分析
    Summary ValiRx Plc (ValiRx) is a life science company that develops therapeutics for the treatment of clinical stage cancer. The company’s products include VAL201-prostate cancer, VAL401-lung cancer, GeneICE – BCL-2, and NAV3 cancer screening test. It uses GeneICE technology, which enables silencing …
  • Vindhya Telelinks Ltd:企業の戦略・SWOT・財務情報
    Vindhya Telelinks Ltd - Strategy, SWOT and Corporate Finance Report Summary Vindhya Telelinks Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • International SOS Pte Ltd:企業の戦略的SWOT分析
    International SOS Pte Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • McConnell Dowell Corp Ltd:企業の戦略的SWOT分析
    McConnell Dowell Corp Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆